Literature DB >> 8777834

Excessive gravitational blood pooling caused by impaired venous tone is the predominant non-cardiac mechanism of orthostatic intolerance.

D H Streeten1, T F Scullard.   

Abstract

1. In a group of 40 patients with orthostatic intolerance due to hypotension and/or tachycardia, we have compared the pathogenetic roles of impaired contractility of the arterioles and the veins by measuring contractile responsiveness of the arterioles, reflected by increases in diastolic blood pressure and of the veins reflected by measurements of reduction in venous diameter during intravenous noradrenaline infusions. 2. Compared with 27 healthy subjects, patients with diffuse autonomic insufficiency showed striking supersensitivity in diastolic blood pressure (six out of eight) and venous constrictive responses (seven out of eight patients) to noradrenaline, consistent with impaired arteriolar and venous innervation. 3. In contrast, the patients with hyperadrenergic orthostatic hypotension (n = 16) and orthostatic tachycardia (n = 16) showed diastolic blood pressure responses to noradrenaline that were almost invariably within the 95% confidence limits of the changes in normal subjects but supersensitive constrictive responses of foot veins in 22 of 32 subjects and subnormal venous responses in two individuals. The rate of noradrenaline infusion calculated to cause 50% of maximal venous constriction (the ED50) was significantly lower in the patients [mean (SEM) 6.8 (1.9) ng/min] than in the normal subjects [mean (SEM) 23.2 (3.0) ng/min, P < 0.025]. 4. The finding of significantly supersensitive foot vein constrictive responses to noradrenaline infusion in the patients of all three groups and supersensitive blood pressure responses exclusively in the patients with diffuse autonomic insufficiency indicates that venous pooling in the legs was the predominant pathogenetic mechanism of orthostatic intolerance in all three types of patients studied. 5. Correction of the orthostatic hypotension and/or tachycardia by external compression in virtually all patients confirmed this conclusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777834     DOI: 10.1042/cs0900277

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

Review 1.  Pathophysiological basis of orthostatic hypotension in autonomic failure.

Authors:  A A Smit; J R Halliwill; P A Low; W Wieling
Journal:  J Physiol       Date:  1999-08-15       Impact factor: 5.182

2.  Cerebrovascular and cardiovascular responses associated with orthostatic intolerance and tachycardia.

Authors:  M P Harms; J J van Lieshout
Journal:  Clin Auton Res       Date:  2001-02       Impact factor: 4.435

3.  Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome.

Authors:  V M Gordon; T L Opfer-Gehrking; V Novak; P A Low
Journal:  Clin Auton Res       Date:  2000-02       Impact factor: 4.435

4.  Vagal and Sympathetic Function in Neuropathic Postural Tachycardia Syndrome.

Authors:  Giris Jacob; Laura Diedrich; Kyoko Sato; Robert J Brychta; Satish R Raj; David Robertson; Italo Biaggioni; André Diedrich
Journal:  Hypertension       Date:  2019-05       Impact factor: 10.190

5.  Gastric emptying in postural tachycardia syndrome: a preliminary report.

Authors:  Ki-Jong Park; Wolfgang Singer; David M Sletten; Phillip A Low; Adil E Bharucha
Journal:  Clin Auton Res       Date:  2013-05-25       Impact factor: 4.435

Review 6.  POTS versus deconditioning: the same or different?

Authors:  Michael J Joyner; Shizue Masuki
Journal:  Clin Auton Res       Date:  2008-08-12       Impact factor: 4.435

Review 7.  Exercise and non-pharmacological treatment of POTS.

Authors:  Qi Fu; Benjamin D Levine
Journal:  Auton Neurosci       Date:  2018-07-04       Impact factor: 3.145

8.  The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients.

Authors:  Merav Barzilai; Giris Jacob
Journal:  Rambam Maimonides Med J       Date:  2015-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.